Benefits
Upper respiratory comfort: lozenges studied for symptom duration
In 100 adults starting lozenges within 24 hours of cold symptoms, symptoms cleared in a median 4.4 days versus 7.6 on placebo, but a 249-child trial found no difference. A pooled analysis of four gluconate lozenge trials found colds 28% shorter, while a recent review of all zinc forms rated the evidence low certainty.
Normal immune function
Zinc is an essential mineral that plays a role in immune function, and it is needed by hundreds of enzymes and for protein and DNA synthesis and wound healing. Most people in the United States get enough from food. Taking 50 mg or more a day for weeks can reduce immune function and copper absorption.
Absorption compared with other zinc forms
In a 14-day crossover study in 12 healthy men, zinc gluconate gave an 18% higher peak and 8% higher total blood zinc level than zinc oxide, though the gluconate group got about 15 percent more zinc. In a tracer study in 15 adults, about 61% of the zinc was absorbed from gluconate and from citrate, versus 50% from oxide. These are absorption measures, not health outcomes.
Mechanism of action
Contact with the mouth and throat (proposed)
Zinc lozenges are dissolved slowly in the mouth, and the gluconate trials that reported shorter colds used this route. The authors of the positive adult trial stated that how zinc acts on cold symptoms remains unknown.
Enzyme and immune roles
Zinc is required for the activity of hundreds of enzymes and takes part in immune function, protein and DNA synthesis, wound healing and cell division. Zinc gluconate supplies the same zinc as other forms once absorbed.
Clinical trials
Randomized, double-blind, placebo-controlled trial of lozenges with 13.3 mg zinc from zinc gluconate every 2 hours while awake, started within 24 hours of symptoms (Mossad et al. 1996, Ann Intern Med).
100 employees of the Cleveland Clinic (50 zinc, 50 placebo).
Symptoms cleared in a median 4.4 days on zinc versus 7.6 days on placebo (p < 0.001), with fewer days of cough, headache, hoarseness, nasal congestion and sore throat. Side effects were more common on zinc (90% vs 62%), including bad taste (80% vs 30%) and nausea (20% vs 4%).
Randomized, double-masked, placebo-controlled trial of 10 mg zinc gluconate glycine lozenges taken 5 or 6 times a day, started within 24 hours of symptoms (Macknin et al. 1998, JAMA).
249 students in grades 1 to 12 in two Cleveland-area school districts.
Time to resolution of cold symptoms did not differ (median 9 days in both groups, p = 0.71), and none of the 9 symptoms improved. Bad taste (60.2% vs 37.9%) and nausea (29.3% vs 16.1%) were more common on zinc.
Meta-analysis of seven placebo-controlled lozenge trials using more than 75 mg zinc a day (Hemila 2017, JRSM Open).
575 people with naturally acquired colds.
Colds were 33% shorter overall (95% CI 21% to 45%): 40% in three acetate trials and 28% in four gluconate trials, a difference between the salts that was not significant. Doses above 100 mg a day did not work better.
Cochrane systematic review of 34 placebo-controlled trials (8,526 participants) of any zinc form for preventing or treating colds (Nault et al. 2024, Cochrane Database Syst Rev).
Children and adults; gluconate lozenges were the most common form in the treatment trials.
Used as treatment, zinc may shorten colds by about 2.4 days (low-certainty evidence, high heterogeneity) and probably raises the risk of non-serious side effects (RR 1.34). Zinc may have little or no effect on preventing colds.